Carbon C 14-pamiparib
Term · Oncology and biomedicine · MLC-T-ONC-012289
An orally bioavailable radioconjugate composed of pamiparib, a nuclear enzyme poly(ADP-ribose) polymerase (PARP) inhibitor, radiolabeled with the radioisotope carbon C 14, with potential use for evaluating the pharmacokinetic profile of pamiparib. Pamiparib targets, binds to and inhibits PARP, which results in the inhibition of tumor cell proliferation and survival. Labeling of pamiparib with the radioactive tracer carbon C 14 allows for the evaluation of pamiparib's pharmacokinetic profile, including its absorption, distribution, metabolism and excretion (ADME).
| Identifier | MLC-T-ONC-012289 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | 14C-pamiparib; [14C]-pamiparib |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-012289",
"term": "Carbon C 14-pamiparib",
"field": "Oncology and biomedicine",
"definition": "An orally bioavailable radioconjugate composed of pamiparib, a nuclear enzyme poly(ADP-ribose) polymerase (PARP) inhibitor, radiolabeled with the radioisotope carbon C 14, with potential use for evaluating the pharmacokinetic profile of pamiparib. Pamiparib targets, binds to and inhibits PARP, which results in the inhibition of tumor cell proliferation and survival. Labeling of pamiparib with the radioactive tracer carbon C 14 allows for the evaluation of pamiparib's pharmacokinetic profile, including its absorption, distribution, metabolism and excretion (ADME).",
"synonyms": [
"14C-pamiparib",
"[14C]-pamiparib"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/carbon-c-14-pamiparib/"
}
Record 4,192 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.